Visualize HL7 Example and Test Instances (vi7eti), pronounced /viːˈsɛtiː/
Disclaimer: FOR TEST AND EXAMPLE PURPOSES ONLY! These web pages are not intended to be used as a source of information on medicines. The web pages are not kept up to date and are for demonstration purposes only. For up-to-date information on a medicine, please consult www.ema.europa.eu/medicines or the package leaflet of your medicine.
BACK TO LIST

Laboratory Report

Patient
Name: Köhler, , Leonhard,
DOB: 19-DEC-1949 (Age: 75)
Gender: male
Address:
Henckweg 97/34
87629 Füssen (Germany)
ID: 5321-442678-4 (ECI)
Report
Date: 18-AUG-2017
Laboratory
dr Ample, Ex
Laboratoire Central Européenne
Boulevard du Jardin Botanique 32
1000 Brussels (Belgium)
Requested by
hier ist kein Ärztehaus
Feistlestraße 2
87629 Füssen (Germany)
Specimen
Collected: 18-AUG-2017

Chemistry

Test 18-AUG-2017 Reference Range Unit
Hemoglobin A1c/Hemoglobin.total in Blood 6.0 H 4.8 - 5.7 %
Glucose [Mass/volume] in Blood 93.0 70 - 140 mg/dL
Urea nitrogen [Mass/volume] in Blood 15.1 7 - 20 mg/dL
Creatinine [Mass/volume] in Blood 1.0 0.6 - 1.3 mg/dL
Calcium [Mass/volume] in Blood 8.6 8.5 - 10.5 mg/dL
Sodium [Moles/volume] in Blood 143.6 135 - 145 mmol/L
Potassium [Moles/volume] in Blood 4.1 3.5 - 5.1 mmol/L
Chloride [Moles/volume] in Blood 106.5 98 - 108 mmol/L
Carbon dioxide, total [Moles/volume] in Blood 26.1 22 - 32 mmol/L
Cholesterol [Mass/volume] in Serum or Plasma 282.1 H 125 - 200 mg/dL
Triglyceride [Mass/volume] in Serum or Plasma 117.1 40 - 150 mg/dL
Cholesterol in LDL [Mass/volume] in Serum or Plasma by Direct assay 210.1 H 0 - 190 mg/dL
Cholesterol in HDL [Mass/volume] in Serum or Plasma 48.6 40 - 60 mg/dL

Annotation

Conclusion and Recommendations based on this report and previous findings known to us
The patient shows elevated HbA1c, indicating suboptimal long-term glucose control, and significantly increased total and LDL cholesterol, suggesting heightened cardiovascular risk. Other parameters, including renal function, electrolytes, and triglycerides, are within normal limits. Recommend further evaluation and management of dyslipidemia and glycemic control.